BAFF / BLyS (蛋白 | 抗体 | cDNA 克隆 | ELISA 试剂盒)

All BAFF / BLyS reagents are produced in house and quality controlled, including 6 BAFF / BLyS Antibody, 40 BAFF / BLyS Gene, 2 BAFF / BLyS IP Kit, 4 BAFF / BLyS Lysate, 6 BAFF / BLyS Protein, 2 BAFF / BLyS qPCR. All BAFF / BLyS reagents are ready to use.

BAFF / BLyS Protein (6)

BAFF / BLyS Antibody (6)

BAFF / BLyS cDNA Clone (40)

NM_006573.3

克隆载体 cDNA 产品

In lentiviral vector

NM_033622.1

克隆载体 cDNA 产品

In lentiviral vector

NM_001161710.2

克隆载体 cDNA 产品

XM_001082247.2

克隆载体 cDNA 产品

In lentiviral vector

BAFF / BLyS Lysate (4)

更多受客户欢迎的产品

BAFF / BLyS 分子背景

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

BAFF / BLyS 参考文献

  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.